Advances in the Management of Tardive Dyskinesia

Advances in the Management of Tardive Dyskinesia

On-Demand Webcast
Program Description

This activity was developed for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician assistances, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with tardive dyskinesia.

Research into TD pathophysiology and treatment targets has led to the advancement of vesicular monoamine transporter 2 (VMAT2) inhibitors, with 2 agents recently approved by the Food and Drug Administration (FDA). Key differences in the pharmacokinetic/pharmacodynamic properties of these newer agents will be examined, as well as clinical outcome data from the ARM-TD, AIM- TD, KINECT-3, the ongoing KINECT-4, and other clinical trials.

Webcast Access

CLICK HERE to access the webcast and for complete accreditation information.

This activity is hosted on the Medscape website. Viewers will need to create an account before accessing the webcast. Please visit or the above access link for more information.


Stanley N. Caroff, MD
Professor of Psychiatry, Perelman School of Medicine
Univeristy of Pennsylvania
Philadelphia, Pennsylvania

Rakesh Jain, MD, MPH
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center School of Medicine
Midland, Texas

Joseph P. McEvoy, MD
Professor of Psychiatry & Health Behavior
I. Clark Case Chair in Psychotic Disorders
Medical College of Georgia
Augusta, Georgia


In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hours.

Grant Support

This activity is supported by an independent educational grant from Teva Pharmaceuticals.